



Omaha Metropolitan Healthcare Coalition COVID-19 Vaccine Quick Reference Guide



School of Pharmacy and Health Professions Center for Drug Information and Evidence-Based Practice

Storage and Handling	Janssen Biotech (JNJ-78436735) ¹⁻³	Novavax, Adjuvanted ⁴⁻⁶		
Dry ice	Do not use; not stored frozen	Do not use; not stored frozen		
Freezer storage	Do not store frozen	Do NOT store frozen		
Refrigerator storage	• 2°C to 8°C	• 2°C to 8°C		
	Protect from light. Do not store frozen.	Protect from light. Do not store frozen.		
Refrigerator thawing	 Vaccine is initially stored frozen by the manufacturer, then shipped at 2°C to 8°C. If vaccine is still frozen upon receipt, thaw at 2°C to 8°C. 	N/A: Vials are stored refrigerated, no need to thaw		
Room temperature thawing	 If needed immediately, thaw at room temperature (max 25°C). At room temperature, a carton of 10 vials will take ~4 hours to thaw, and an individual vial will take ~1 hour to thaw. Unpunctured vials may be stored between 9°C to 25°C for up to 12 hours. 	N/A: Vials are stored refrigerated, no need to thaw		
In vial	 Stable for up to 6 hours from first puncture at 2°C to 8°C or up to 2 hours at room temp (max 25°C) Discard vial if not used within these times 	 After first needle puncture, store between 2°C to 25°C for up to 6 hours Discard vial 6 hours after first needle puncture 		
In syringe	 Filled syringes stable for up to 6 hours stored in refrigerator (2°C to 8°C) or 2 hours stored at room temperature (max 25°C) after first vial puncture 	2°C to 25°C for up to 6 hours		
FDA status	• EUA	EUA: two-dose primary series		
Age minimum	18 years	12 years		
Dose	• 0.5 mL	• 0.5 mL		
Dose interval dose 1 to 2	N/A; Single dose	3 weeks apart		
Booster dose	 0.5 mL; Moderna or Pfizer-BioNTech as a booster dose is preferred to Janssen in most situations 	• N/A		
Booster dose interval	At least 2 months after primary series	• N/A		
Dilution required? Additional instructions	 DO NOT DILUTE Before withdrawing each dose of vaccine, carefully mix the contents of the multi-dose vial by swirling gently in an upright position for 10 seconds. Do not shake. 	 DO NOT DILUTE Gently swirl vial before each dose withdrawal. Do not shake. 		
# of primary series doses/vial	• 5 doses/vial (NDC 59676-580-15)	• 10 doses/vial (NDC 80631-100-01)		
Determining # of vials to thaw	Vials are stored refrigerated, no need to thaw	Vials are stored refrigerated, no need to thaw		
Additional Information	Call Janssen Medical Information: 1-800-565-4008	Call Novavax Medical Information: 1-844-668-2829		
NOTES FOR ALL COVID-19 VACCINES				

Storage and Handling	Moderna (Spikevax [mRNA-1273]) ⁷⁻¹⁴			
Products	MONOVALENT COVID19 VACCINES	BIVALENT COVID19 VACCINE		
Vial types and # doses	MAGENTA LABEL AND DARK BLUE CAP VIAL	DARK BLUE LABEL WITH GRAY BORDER		
per vial	10 doses; NDC 80777-279-99	5 dose; NDC: 80777-282-99		
	TEAL LABEL AND DARK BLUE CAP VIAL			
	5 doses; NDC 80777-277-99			
	PURPLE LABEL AND DARK BLUE CAP VIAL			
	5 doses; NDC 80777-275-05			
	LIGHT BLUE LABEL AND RED CAP VIAL			
	11-Dose vial (10-11 doses) NDC 80777-273-99;			
	15-Dose vial (13-15 doses) NDC 80777-273-98			
Dry ice	Do not use	Do not use		
Freezer storage	-50°C to -15°C; Do not store below -50°C	 -50°C to -15°C (-58°F to 5°F) 		
	 Keep in original packaging; Protect from light until ready to use 	Keep in original packaging; Protect from light until ready to use		
Refrigerator storage	2°C to 8°C for up to 30 days	• 2°C to 8°C (36°F to 46°F) for up to 30 days		
Refrigerator thawing	MAGENTA/TEAL/PURPLE Label vials:	• Thaw between 2°C to 8°C (36°F to 46°F) for 2 hours. Let each vial stand		
0 0	• Thaw between 2°C to 8°C for 2 hours. Let each vial stand at room temperature for 15 mins before administering.	at room temperature for 15 minutes before administering		
	LIGHT BLUE LABEL vials:	• Vials may be refrigerated between 2°C to 8°C (36°F to 46°F) for up to 30		
	 5.5 mL (Max 11 Dose) Vial: Thaw at 2°C to 8°C for 2.5 hours 	days prior to first use		
	• 7.5 mL (Max 15 Dose) Vial: Thaw at 2°C to 8°C for 3 hours	Vials should be discarded 12 hours after the first puncture		
	After thawing, let each vial stand at room temperature for 15 minutes prior to administering.	Do not refreeze once thawed		
Room temperature	MAGENTA/TEAL/PURPLE Label vials:	 Thaw between 15°C to 25°C (59°F to 77°F) for 45 minutes. 		
thawing	Thaw between 15°C to 25°C for 45 mins	• Vials may be stored between 8°C to 25°C (46°F to 77°F) for a total of 24		
•	• Unpunctured vials may be stored at 8°C to 25°C for up to 24 hrs.	hours		
	LIGHT BLUE LABEL vials:	• Vials should be discarded 12 hours after the first puncture		
	 5.5 mL vial (Max 11 Dose) Vial: Thaw at 15°C to 25°C for 1 hour 	• Total storage at 8°C to 25°C (46°F to 77°F) must not exceed 24 hours		
	• 7.5 mL (Max 15 Dose) Vial: Thaw at 15°C to 25°C for 90 mins	 Do not refreeze once thawed 		
	• Unpunctured vials may be stored at 8°C to 25°C for up to 24 hrs.			
In vial	Stable for up to 12 hours from initial vial puncture at 2°C to 25°C; Discard after 12 hours	 Stable for up to 12 hours from initial vial puncture at 2°C to 25°C; Discard after 12 hours 		
In syringe	 Stable for up to 12 hours from initial vial puncture (labeling and time stamp recommended) 	• Stable for up to 12 hours from initial vial puncture		
	 Store in refrigerator (2°C to 8°C) or at room temperature (15°C to 25°C); Keep out of direct sunlight 	• Store at 2°C to 8°C or 15°C to 25°C; Keep out of direct sunlight		
FDA status	FDA-approved EUA:	EUA		
	Primary two-dose series in Primary 2-dose series in individuals 6 months through 17 years old	• Single-booster dose (Moderna Bivalent COVID19: DARK BLUE LABEL) in		
	individuals age ≥ 18 years • Primary 3-dose series for certain immunocompromised patients age ≥ 6 months	adults ≥ 18 years at least 2 months after any authorized or approved		
	 First booster for individuals ≥ 18 years who have received primary series with 	monovalent COVID19 vaccine for:		
	Moderna or another authorized/approved COVID19 vaccine	 Completion of primary COVID19 vaccination OR 		
	 2nd booster for people ≥ 50 years or certain immunocompromised ≥ 18 years 	\circ Receipt of the most recent COVID19 booster dose		
Age minimum	6 months	 ≥ 18 years 		
Dose	• 0.5 mL for ≥ 12 years (LIGHT BLUE LABEL)	N/A (Booster only)		
	• 0.5 mL for 6-11 years (PURPLE* or TEAL Label); *PURPLE label vial states on vial "BOOSTER DOSES ONLY" but it may be			
	used for primary dose series for individuals 6-11 years old			
	0.25 mL for 6 months to 5 years (MAGENTA LABEL)			
Dose interval dose 1 to 2	• 4 weeks	• N/A; Booster only - May be given 2 months after the completion of		
	• 3^{rd} primary series dose ≥ 1 month after the 2^{nd} dose is authorized in patients (≥ 6 months) who have undergone solid	primary vaccination with any authorized or approved monovalent		
	organ transplant or are diagnosed with conditions considered to have an equivalent level of immunocompromised	COVID19 vaccine		
Booster dose	0.25 mL (LIGHT BLUE Label)	• 0.5 mL		
	• 0.5 mL (PURPLE Label)	 Only for ≥ 18 years 		
	 Only for ≥ 18 years old 			
Booster dose interval	At least 5 months after primary series	 May be given to adults ≥ 18 years at least 2 months after completion of 		
(after receiving primary	 A 2nd booster may be given ≥ 4 months after 1st booster for individuals ≥ 50 years old and certain immunocompromised 	primary vaccination OR receipt of the most recent booster dose with		
series)	adults ≥ 18 years old	any authorized or approved monovalent COVID19 vaccine		
Dilution required?	DO NOT DILUTE	DO NOT DILUTE		
Additional instructions	Swirl gently after thawing and between each withdrawal. DO NOT SHAKE .	Swirl gently after thawing and between each withdrawal. DO NOT		
	 Pierce stopper at different site each time; Do not puncture individual vial stopper more than 20 times. 	SHAKE.		

Storage and Handling	Pfizer-BioNTech (Comirnaty [BNT162b2]) ¹⁵⁻²⁴		
Products	MONOVALENT COVID19 VACCINES	BIVALENT COVID19 VACCINE	
	PURPLE cap and label vial	GRAY cap and label with gray borders	
	6-7 doses; NDC 59267-1000-3; 59267-1000-2	1 dose (SDV); NDC: 59267-1401-1	
	GRAY cap and label vial	6 doses (MDV); NDC 59267-0304-2; 59267-0304-3	
	6-7 doses; NDC 59267-1025-4; 59267-1025-3		
	ORANGE cap and label vial		
	10 doses; NDC 59267-1055-4		
	MAROON cap and label vial		
	10 doses; NDC 59267-0078-4		
Dry ice	• Thermal shipping container may be used as temporary storage ≤ 30 days from delivery with proper dry ice replenishment.	 Thermal shipping container may be used as temporary storage ≤ 30 days from delivery with proper dry ice replenishment. 	
Freezer storage	-90°C to -60°C until expiration date; Keep in original packaging and protect from light until ready to use	• May be stored in ultra-low temperature freezer at-90°C to -60°C for up	
	• PURPLE cap vials may be stored at -25°C to -15°C for up to 2 weeks, and then may be returned <u>one</u> -time to -90°C to -60°C	to 12 months from date of manufacture	
	storage (track storage time/temperature)	 <u>DO NOT STORE</u> vials at -25°C to -15°C 	
	• <u>DO NOT STORE</u> GRAY/ORANGE/MAROON vials in freezer (-25 °C to -15 °C).	 Once vials are thawed, they should not be refrozen 	
	Vials expire 12 months from manufactured date regardless of storage		
Refrigerator storage	• 2°C to 8°C for up to 1 month for PURPLE cap vials and 10 weeks for GRAY/ORANGE/MAROON cap vials	• 2°C to 8°C for up to 10 weeks	
-	 Minimize room light exposure and avoid exposure to direct sunlight/ultraviolet light 		
Refrigerator thawing	 Thaw in refrigerator (2°C to 8°C); may take up to 6 hours depending on cap vial color and/or number of vials 	• Thaw at 2°C to 8°C; may take 2 hours (SDV) to 6 hours (MDV)	
	 Vials that require dilution must be at room temperature at least 30 minutes prior to diluting 	 Allow vial to sit at room temp for 30 minutes 	
Room temperature	 Thaw at room temperature (up to 25°C) for 30 minutes 	 Allow vials to thaw at room temp (up to 25°C) for 30 minutes 	
thawing	 Vials that require dilution must be at room temperature for 30 minutes prior to diluting 	 Thaw at room temp (8°C to 25°C) for a total 12 hours prior to 1st 	
	PURPLE cap vials must be diluted within 2 hours of reaching room temperature	puncture. After 1 st puncture, the MDV should be stored between 2°C to	
	 MAROON/ORANGE/GRAY cap vials may be stored at room temperature (8°C to 25°C) for 12 hours prior to dilution 	25°C (35°F to 77°F), and discarded 12 hours after 1 st puncture	
In vial	 PURPLE CAP VIALS: Stable for up to 6 hours from dilution at 2°C to 25°C; Discard after 6 hours 	 Stable in vial for up to 12 hours after 1st puncture when stored between 	
in via	GRAY/ORANGE/MAROON cap vials: Stable for up to 12 hours from dilution at 2°C to 25°C; Discard after 12 hours	2°C to 25°C (35°F to 77°F)	
In syringe	 PURPLE CAP VIALS: Stable for up to 24 hours from dilution at 2°C to 30°C ± 2°C in polycarbonate and polypropylene 	 Stable in syringe for up to 12 hours when stored between 2°C to 25°C 	
in syninge	syringes with stainless steel needles, with ≤ 6 hours at room temp (up to 30°C) and remainder at (2°C to 8°C)	(35°F to 77°F)	
	 GRAY/ORANGE cap vials: Stable for up to 24 hours from dilution at 2°C to 30°C ± 2°C in polycarbonate and polypropylene 	(35 F (077 F)	
	syringes with stainless steel needles, with ≤ 12 hours at room temp (up to 30°C) and remainder in refrigerator (2°C to 8°C)		
	MAROON cap: use immediately		
FDA status	FDA-approved EUA:	EUA	
FDA Status			
	 Primary 2- Primary 2-dose series in 5+ years; 3rd primary series dose in 5+ years with certain immunocompromising conditions; booster dose 	 Single-booster dose (Pfizer Bivalent COVID19: GRAY cap and label with gray border) in ≥ 12 years at least 2 months after any authorized or 	
		approved monovalent COVID19 vaccine for:	
	age \geq 12 yrs • Primary 3-dose series for 6 months to < 5 years;	 Completion of primary COVID19 vaccination OR 	
	 Children turning from 4 to 5 years of age between any 2 doses in the primary series may receive: 2-dose primary series with the Pfizer-BioNTech COVID-19 Vaccine authorized for use in 	 Receipt of the most recent COVID19 vaccination OK 	
	individuals 5 through 11 years of age OR	O Receipt of the most recent covid 15 booster dose	
	 3-dose primary series initiated with the Pfizer-BioNTech COVID-19 Vaccine authorized for use in 		
	individuals 6 months through 4 years		
Age minimum	6 months	 ≥ 12 years 	
Dose	0.3 mL for 12+ years (PURPLE or GRAY cap vial)		
DUSC	 0.2 mL for 5-11 years (ORANGE cap vial) 	A NIA POOSTER ONLY	
	 0.2 mL for 5-11 years (ORANGE cap vial) 0.2 mL for 6 months to < 5years (MAROON cap vial) 	• N/A; BOOSTER ONLY	
Doco intorval doco 1 to 2			
Dose interval dose 1 to 2	Age 6 months to < 5 years (MAROON): ≥ 5 years:	• N/A; BOOSTER ONLY	
	 3 doses; 3 weeks 3 weeks apart between doses 1 and 2 3rd primary series dose ≥ 28 days after the 2nd dose is authorized in patients (≥ 		
	• Dose 3 at least 8 weeks after dose 2 5 years) who have undergone solid organ transplant or are diagnosed with conditions considered to have an equivalent level of immunocompromised		
Poostor doso			
Booster dose	• 0.3 mL (for 12+ years only) (PURPLE or GRAY cap vial)	 0.3 mL (≥ 12 years) 	
December dece 1 1	0.2 mL (for 5-11 years only) (ORANGE cap vial)		
Booster dose interval	At least 5 months after primary series	• \geq 12 years at least 2 months after completion of primary vaccination OR	
(after receiving primary	• A 2^{nd} booster may be given ≥ 4 months after 1^{st} booster for individuals ≥ 50 years old and certain immunocompromised	receipt of the most recent booster dose with any authorized or	
series)	patients ≥ 12 years old (PURPLE or GRAY cap vial)	approved monovalent COVID19 vaccine	

	Pfizer-BioNTech (Comirnaty [BNT162b2]) ¹⁵⁻²⁴	
Products	MONOVALENT COVID19 VACCINES	BIVALENT COVID19 VACCINE
Dilution required?	PURPLE cap and label vial	DO NOT DILUTE
Additional instructions	• DILUTE	 Before use, mix by inverting vial gently 10 times; <u>DO NOT SHAKE</u>
	• After vial reaches room temperature, invert vial 10 times; dilute with 1.8 mL of Preservative-Free 0.9% NS and remove 1.8	 Prior to mixing, the thawed vaccine may contain white to off-white
	mL of air from vial; invert vial 10 times. <u>DO NOT SHAKE.</u>	opaque amorphous particles
	Must be diluted within 2 hours of reaching room temperature	 After mixing, the vaccine should appear as a white to off-white
	GRAY cap and label vial	suspension with no visible particles
	DO NOT DILUTE	
	• Before withdrawing each dose of vaccine, carefully mix by inverting vaccine vial gently 10 times. DO NOT SHAKE.	
	ORANGE cap and label vial	
	• DILUTE	
	• After vial reaches room temperature invert vial 10 times; dilute with 1.3 mL of <u>Preservative-Free</u> 0.9% NS and remove 1.3	
	mL of air from vial; invert vial 10 times. <u>DO NOT SHAKE.</u>	
	MAROON cap and label vial	
	• DILUTE	
	• Each vial must be thawed before dilution either in the refrigerator (2 °C to 8 °C) or room temperature (up to 25 °C)	
	Mix by gently inverting vial 10 times. DO NOT SHAKE.	
	• Dilute the vial contents using 2.2 mL of sterile 0.9% NS and remove 2.2 mL air from vial.	
	Gently invert the vial 10 times to mix; DO NOT SHAKE.	
Additional Information	Call Pfizer Medical Information: 1-800-438-1985	

References

- 1. Janssen- COVID-19 Vaccine. Fact Sheet for Healthcare Providers Administering Vaccine. Revised 5/5/2022. Available at: https://www.janssenlabels.com/emergency-use-authorization/Janssen+COVID-19+Vaccine-HCP-fact-sheet.pdf. Accessed: July 6, 2022.
- 2. FDA Janssen COVID-19 Vaccine. Revised 1/11/2022. Available at: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/janssen-covid-19-vaccine. Accessed: January 13, 2022.
- 3. Tina Berencsi, RN Janssen Drug Information Center. January 14, 2022.
- 4. Novavax- COVID-19 Vaccine. Fact Sheet for Healthcare Providers Administering Vaccine. Revised 7/13/2022. Available at: https://www.fda.gov/media/159897/download Accessed: July 15, 2022.
- 5. Maria M., RN Novavax Medical Information Center. July 15, 2022.
- 6. Novavax COVID-19 Vaccine, Adjuvanted Storage and Stability Letter. Novavax Medical Information Center. Last updated: 7/13/22; Accessed: 7/15/22.
- 7. Moderna COVID-19 Vaccine. Storage & Handling. https://www.modernatx.com/covid19vaccine-eua/providers/storage-handling.pdf. Updated October 20, 2021. Accessed: January 13, 2022.
- 8. Moderna. Provided in email communication with Moderna Medical Information.
- 9. Moderna COVID-19 Vaccine. Fact Sheet for Healthcare Providers Administering Vaccine: Primary Series 6 months through 5 years. Revised 6/17/2022. Available at: https://www.fda.gov/media/159307/download. Accessed: July 7, 2022.
- 10. Moderna COVID-19 Vaccine. Fact Sheet for Healthcare Providers Administering Vaccine: Primary Series 6 years through 11 years. Revised 6/17/2022. Available at: https://www.fda.gov/media/159308/download. Accessed: July 7, 2022.
- 11. Moderna COVID-19 Vaccine. Fact Sheet for Healthcare Providers Administering Vaccine: Primary Series for 12 years or older and booster doses for 18 years and older. Revised 6/17/2022. Available at: https://www.fda.gov/media/157233/download. Accessed: 7/7/22
- 12. Moderna COVID-19 Vaccine. Fact Sheet for Healthcare Providers Administering Vaccine: Moderna COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5). Revised 8/31/2022. Available at: https://www.fda.gov/media/161318/download; Accessed: 9/2/22
- 13. Moderna COVID-19 Vaccine Presentations. Available at: <u>https://www.fda.gov/media/159306/download</u>. Accessed July 7, 2022.
- 14. Nebraska Medicine. Moderna COVID Vaccination Clinic Procedures (1-15-2021).
- 15. Pfizer-BioNTech COVID-19 Vaccine. http://labeling.pfizer.com/ShowLabeling.aspx?id=14471. Updated June 17, 2022. Accessed July 6, 2022.
- 16. Pfizer-BioNTech COVID-19 Vaccine. Thermal Shipping Container Dry Ice Replenishment Instructions. https://www.cvdvaccine-us.com/images/pdf/DryIceReplenishment.pdf. Updated June 17, 2022. Accessed: July 6, 2022.
- 17. Pfizer-BioNTech COVID-19 Vaccine. Questions and Answers About Pfizer-BioNTech COVID-19 Vaccine. https://www.cvdvaccine-us.com/fags. Updated June 17, 2022. Accessed: July 6, 2022.
- 18. Pfizer-BioNTech COVID-19 Vaccine. Storage and Handling of DILUTED VIALS Outside of Recommendations in the EUA Prescribing Information. Provided in email communication with Pfizer Medical Information.
- 19. Pfizer-BioNTech COVID-19 Vaccine. Fact Sheet for Healthcare Providers Administering Vaccine. Revised 1/3/2022. Available at: https://www.fda.gov/media/144413/download. Accessed: January 13, 2022.
- 20. Pfizer-BioNTech COVID-19 Vaccine, Fact Sheet for Healthcare Providers Administering Vaccine: Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5). Revised 8/31/2022. Available at: https://www.fda.gov/media/161327/download; Accessed: 9/2/22.
- 21. Pfizer-BioNTech letter to Austin Jantrakul, PharmD Candidate. Storage of the Vaccine Outside of Recommendations in the Prescribing Information DURING and AFTER DILUTION. (1/14/2022).
- 22. Pfizer-BioNTech COVID-19 Vaccine. https://labeling.pfizer.com/ShowLabeling.aspx?id=17227&format=pdf. Updated June 17, 2022. Accessed: July 7, 2022
- 23. Amy R, PharmD Pfizer-BioNTech Drug Information Center. September 6, 2022.
- 24. Nebraska Medicine. Pfizer COVID Vaccination Clinic Procedures (1-15-2021).